Testogel Application in the Menopause: Making a Difference to the Lives of Women

Aims Benefit has been shown from testosterone therapy given to postmenopausal women experiencing reduced sexual desire. Specifically, an increased frequency of satisfying encounters and intensity desire better response with in a number studies spanning more than 35 years. Androgen related improvement energy, mood, well-being, self-perception, some parameters sexuality (libido, activity, arousal, excitability satisfaction. Methods In group 10 menopausal applying Testogel 16.2mg/g at the dose 20.25 mg every 3-4 days as part their usual care together oestrogen +/- progestogen HRT, we measured serum free androgen index (FAI) pre-application 24 hours after its application. Testosterone was by mass spectrometry. The Female Sexual functioning Index (FSFI) completed women. Results range duration treatment 6 months-23 All subjectively reported function administered most recently Testogel. median score 24.5/36 (25-75% interquartile 18-28) highest domain scores for satisfaction arousal (4.2/6) moderate orgasm (3.6/6) lowest lubrication (2.4/6) no issues re pain on intercourse, supplementation. Mean pre-Testogel administration level (corresponding trough level) 0.85: 0.6-1.2 nmol/L (median: 25-75% range) rising post 3.6: 1.9-4.8 (Reference is up to1.4 nmol/L). rise not associated any untoward effects terms hirsutism/acne. Conclusion our case series experienced benefit gel function. FSFI indicated reasonable this treated HSDD. increase FAI application / manifest consequences. supplementation approved hypoactive disorder (HSDD) UK other parts Europe. This matter needs be addressed priority all stakeholders so that medication can made freely available.